CoChat

Heart Failure Outcomes in Clinical Trials of Glucose-Lowering Agents in Patients with Diabetes

Open access
Fitchett, David H., Udell, Jacob A., Inzucchi, Silvio E. · 2017 · European Journal of Heart Failure
Cited by 102

The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.

Abstract

Diabetes is a major risk factor for heart failure (HF). Patients with diabetes have a high incidence of both clinical HF and subclinical LV dysfunction. Although intensive glucose lowering does not appear to impact on HF outcomes, the choice of glucose-lowering agents plays an important role in the development of HF and related cardiovascular outcomes. Whilst metformin and insulin appear to have little impact on HF progression, the role of sulphonylurea agents in this patient population remains uncertain. Thiazolidinediones (TZDs) are associated with a significant risk of HF progression and are best avoided in patients at risk. The incretin-based therapies (GLP agonists and DPP-4 inhibitors) are generally not associated with any HF interaction. However, a small increase in HF admissions was observed with the DPP-4 inhibitor saxagliptin. The GLP-1 agonist liraglutide was recently shown to reduce cardiovascular and all-cause mortality, yet hospitalization for HF was not significantly reduced. The SGLT2 inhibitor empagliflozin was shown to reduce HF admissions and cardiovascular mortality in patients with prior cardiovascular disease including HF. These recent data showing improved outcomes with a glucose-lowering category provide a novel strategy to improve survival and reduce morbidity in diabetic patients at high cardiovascular disease risk.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/ejhf.633

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 41

  1. Schocken, 2008, Circulation, 117, 2544, 10.1161/CIRCULATIONAHA.107.188965 · DOI · Paper page
  2. Kannel, 1974, Role of diabetes in congestive heart failure: the Framingham study, Am J Cardiol, 34, 29, 10.1016/0002-9149(74)90089-7 · DOI · Paper page
  3. Dei Cas, 2015, Concomitant diabetes mellitus and heart failure, Curr Probl Cardiol, 40, 7, 10.1016/j.cpcardiol.2014.09.002 · DOI
  4. Lund, 2014, Association between cardiovascular vs. non-cardiovascular co-morbidities and outcomes in heart failure with preserved ejection fraction, Eur J Heart Fail, 16, 992, 10.1002/ejhf.137 · DOI
  5. Bertoni, 2004, Heart failure prevalence, incidence, and mortality in the elderly with diabetes, Diabetes Care, 27, 699, 10.2337/diacare.27.3.699 · DOI · Paper page
  6. Cubbon, 2013, Diabetes mellitus is associated with adverse prognosis in chronic heart failure of ischaemic and non-ischaemic aetiology, Diab Vasc Dis Res, 10, 330, 10.1177/1479164112471064 · DOI · Paper page
  7. Cubbon, 2014, Prospective development and validation of a model to predict heart failure hospitalisation, Heart, 100, 923, 10.1136/heartjnl-2013-305294 · DOI · Paper page
  8. Gotsman, 2014, Impaired fasting glucose: a predictor of reduced survival in patients with heart failure, Eur J Heart Fail, 16, 1190, 10.1002/ejhf.146 · DOI
  9. Poulsen, 2010, Left ventricular diastolic function in type 2 diabetes mellitus: prevalence and association with myocardial and vascular disease, Circ Cardiovasc Imaging, 3, 24, 10.1161/CIRCIMAGING.109.855510 · DOI
  10. Fang, 2004, Relationship between longitudinal and radial contractility in subclinical diabetic heart disease, Clin Sci (Lond), 106, 53, 10.1042/CS20030153 · DOI · Paper page
  11. Nakai, 2009, Subclinical left ventricular dysfunction in asymptomatic diabetic patients assessed by two-dimensional speckle tracking echocardiography: correlation with diabetic duration, Eur J Echocardiogr, 10, 926, 10.1093/ejechocard/jep097 · DOI
  12. McMurray, 2014, Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored, Lancet Diabetes Endocrinol, 2, 843, 10.1016/S2213-8587(14)70031-2 · DOI · Paper page
  13. Aguilar, 2009, Relationship of hemoglobin A1C and mortality in heart failure patients with diabetes, J Am Coll Cardiol, 54, 422, 10.1016/j.jacc.2009.04.049 · DOI · Paper page
  14. Leung, 2016, Impact of improved glycemic control on cardiac function in type 2 diabetes mellitus, Circ Cardiovasc Imaging, 9, 10.1161/CIRCIMAGING.115.003643 · DOI
  15. Pocock, 2006, Predictors of mortality and morbidity in patients with chronic heart failure, Eur Heart J, 27, 65, 10.1093/eurheartj/ehi555 · DOI · Paper page
  16. Skott, 1989, Effects of insulin on kidney function and sodium excretion in healthy subjects, Diabetologia, 32, 694, 10.1007/BF00274259 · DOI
  17. Rocchini, 1989, Insulin and renal sodium retention in obese adolescents, Hypertension, 14, 367, 10.1161/01.HYP.14.4.367 · DOI · Paper page
  18. 1998, Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group, Lancet, 352, 837, 10.1016/S0140-6736(98)07019-6 · DOI · Paper page
  19. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group, 1998, Lancet, 352, 854, 10.1016/S0140-6736(98)07037-8 · DOI · Paper page
  20. Eurich, 2013, Comparative safety and effectiveness of metformin in patients with diabetes mellitus and heart failure: systematic review of observational studies involving 34,000 patients, Circ Heart Fail, 6, 395, 10.1161/CIRCHEARTFAILURE.112.000162 · DOI · Paper page
  21. McAlister, 2008, The risk of heart failure in patients with type 2 diabetes treated with oral agent monotherapy, Eur J Heart Fail, 10, 703, 10.1016/j.ejheart.2008.05.013 · DOI · Paper page
  22. Nesto, 2003, American Heart Association, American Diabetes Association. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003, Circulation, 108, 2941, 10.1161/01.CIR.0000103683.99399.7E · DOI · Paper page
  23. Gilbert, 2015, Heart failure in diabetes: effects of anti-hyperglycaemic drug therapy, Lancet, 385, 2107, 10.1016/S0140-6736(14)61402-1 · DOI · Paper page
  24. Karalliedde, 2007, Thiazolidinediones and their fluid-related adverse effects: facts, fiction and putative management strategies, Drug Saf, 30, 741, 10.2165/00002018-200730090-00002 · DOI
  25. Emoto, 2006, Plasma concentrations of vascular endothelial growth factor are associated with peripheral oedema in patients treated with thiazolidinedione, Diabetologia, 49, 2217, 10.1007/s00125-006-0313-5 · doi:10.1007/s00125-006-0313-5
  26. St John Sutton, 2002, A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes, Diabetes Care, 25, 2058, 10.2337/diacare.25.11.2058 · DOI · Paper page
  27. Dargie, 2007, A randomized, placebo-controlled trial assessing the effects of rosiglitazone on echocardiographic function and cardiac status in type 2 diabetic patients with New York Heart Association Functional Class I or II Heart Failure, J Am Coll Cardiol, 49, 1696, 10.1016/j.jacc.2006.10.077 · DOI · Paper page
  28. Home, 2009, Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial, Lancet, 373, 2125, 10.1016/S0140-6736(09)60953-3 · DOI · Paper page
  29. Nikolaidis, 2004, Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy, Circulation, 110, 955, 10.1161/01.CIR.0000139339.85840.DD · DOI · Paper page
  30. Margulies, 2014, GLP-1 agonist therapy for advanced heart failure with reduced ejection fraction: design and rationale for the functional impact of GLP-1 for heart failure treatment study, Circ Heart Fail, 7, 673, 10.1161/CIRCHEARTFAILURE.114.000346 · DOI · Paper page
  31. Mulvihill, 2014, Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitors, Endocr Rev, 35, 992, 10.1210/er.2014-1035 · DOI · Paper page
  32. Hocher, 2012, Renal and cardiac effects of DPP4 inhibitors—from preclinical development to clinical research, Kidney Blood Press Res, 36, 65, 10.1159/000339028 · DOI
  33. Zannad, 2015, Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial, Lancet, 385, 2067, 10.1016/S0140-6736(14)62225-X · DOI · Paper page
  34. Filion, 2016, A multicenter observational study of incretin-based drugs and heart failure, N Engl J Med, 374, 1145, 10.1056/NEJMoa1506115 · DOI · Paper page
  35. Yu, 2015, Incretin-based drugs and the risk of congestive heart failure, Diabetes Care, 38, 277, 10.2337/dc14-1459 · DOI · Paper page
  36. Majewski, 2015, Blood pressure reduction: an added benefit of sodium–glucose cotransporter 2 inhibitors in patients with type 2 diabetes, Diabetes Care, 38, 429, 10.2337/dc14-1596 · DOI · Paper page
  37. Desai, 2013, Hemoglobin concentration in acute decompensated heart failure: a marker of volume status?, J Am Coll Cardiol, 61, 1982, 10.1016/j.jacc.2013.02.021 · DOI
  38. Duarte, 2015, Prognostic value of estimated plasma volume in heart failure, JACC Heart Fail, 3, 886, 10.1016/j.jchf.2015.06.014 · DOI · Paper page
  39. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators, 1991, N Engl J Med, 325, 293, 10.1056/NEJM199108013250501 · DOI · Paper page
  40. 1999, Lancet, 353, 2001, 10.1016/S0140-6736(99)04440-2 · DOI · Paper page
  41. Pitt, 1999, The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators, N Engl J Med, 341, 709, 10.1056/NEJM199909023411001 · DOI · Paper page

Cited by

See all 102

Metadata

Authors
Fitchett, D. H., Udell, J. A., & Inzucchi, S. E.
Venue
European Journal of Heart Failure
Published
2016-09-21
Volume
19
Issue
1
Pages
43-53
ISSN
  • 1388-9842 (ISSN-L)
  • 1879-0844
OpenAlex
W2464585615
Cited by
102
References
34
FWCI
17.90
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.